ADVERSE EVENTS FOLLOWING PENTAVALENT VACCINE ADMINISTRATION: A DESCRIPTIVE STUDY IN THE INDIAN CONTEXT
Kejadian Ikutan Pasca Imunisasi (KIPI) Setelah Pemberian Vaksin Pentavalen: Studi Deskriptif dalam Konteks India
Downloads
Background: Immunization is one of the best ways to prevent childhood diseases. The pentavalent vaccine protects against five serious illnesses with fewer injections. It is cost-effective and usually causes fewer adverse events following immunization (AEFI). However, there are still limited data on AEFI after giving the pentavalent vaccine, compared to giving the DPT, Hep-B, and Hib vaccines separately. Purpose: To determine the proportion and factors associated with adverse events following immunization with pentavalent vaccines. Methods: This was a descriptive study conducted at an immunization clinic in a tertiary care center in India between January 2023 and December 2023. The study population consisted of all infants attending the clinic for vaccination, and all eligible infants receiving pentavalent vaccines were included in the study. The study was done to understand the frequency and type of AEFIs and to ensure the vaccine safety. Results: A total of 93 infants were included in this study, and 264 adverse events were noted in our study. Fever was the most common presenting adverse effect (22.73 %), other adverse effects were pain at injection site (21.21%), swelling at injection site (15.53%), redness at site of injection (14.39%), 10.60% held their leg back due to pain, persistent crying (9.47%) and abscess formation (4.55 %.), and seizures (1.52%). Conclusion: Most of the adverse effects observed in present study were of mild nature and of non-serious type. No major AEFI or permanent damage was noted in our study. The benefits of vaccination far outweigh the risks.
Mittal S, Rawat CMS, Gupta A, Solanki HK, Singh RK. Adverse events following immunization among children under two years of age: a prospective observational Study From North India. Cureus. 2023;15(4):1–8.
Lindstrand A, Cherian T, Chang-Blanc D, Feikin D, O’Brien KL. The world of immunization: achievements, challenges, and strategic vision for the next decade. J Infect Dis. 2021;224(Supplement_4):S452–67.
Ministry of Health and Family Welfare. Pentavalent vaccine [Internet]. 2012.
Li X, Mukandavire C, Cucunubá ZM, Echeverria Londono S, Abbas K, Clapham HE, et al. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet. 2021;397(10272):398–408.
Ministry of Health and Family Welfare Government of India. National health policy 2017. 2017.
Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front Microbiol. 2020;11:1526.
Chen RT, DeStefano F. Vaccine adverse events: causal or coincidental? Lancet. 1998;351(9103):611–2.
Das MK. Adverse events following immunization-the known unknowns and black box: based on 10th Dr. IC Verma excellence award for young pediatricians delivered as oration on 9th Oct. 2022. Indian J Pediatr. 2023;90(8):817–25.
Bellavite P. Causality assessment of adverse events following immunization: the problem of multifactorial pathology. F1000Research. 2020;9:170.
Maizare HI, Tsiga-Ahmed FI, Jibo AM, Adamu AL, Jalo RI, Magaji A, et al. Prevalence and patterns of adverse events following immunisation among children less than 24 months attending immunisation clinics in Kano, Nigeria. Ann African Med Res. 2021;4(1).
Dixit P, Prashant P, Gera V, Bansal A. AEFI (Adverse Events Following Immunization) among children less than 2 years following pentavalent vaccine-a cross study in India. J Popul Ther Clin Pharmacol. 2024;31(2):136–44.
Xavier MAS, Mazumder M Das, Kumar SP. A mixed cohort study on adverse events following pentavalent vaccine and its perception among parents. Int J Curr Pharm Rev Res [Internet]. 2023;15(12):470–4.
Pan X, Lv H, Liang H, Wang Y, Shen L, Chen F, et al. Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. Hum Vaccin Immunother. 2022;18(1):2021711.
Izadi S, Mohammadi M, Sartipi M, Karami M, Karimi H. Acute adverse events following immunization with DTP-HB-Hib pentavalent vaccine in the first year of life. East Mediterr Heal J [Internet]. 2023 Jan 19;29(1):6–14.
Sharma N, Pugazhendi S, Semwal J, Prakash K. Adverse events following immunization among children during primary immunizations in selected health facility of Himachal Pradesh. Indian J Community Heal. 2023;35(4):502–9.
Ekrami Noghabi M, Saffar MJ, Rezai S, Saffar H, Saffar H, Hosseinzadeh F, et al. Immunogenicity and complications of the pentavalent vaccine in Iranian children. Front Pediatr. 2021;9:716779.
Bansal S. Adverse events following immunization with pentavalent vaccine in a tertiary care hospital. Int J Contemp Pediatr [Internet]. 2017 Dec 21;5(1):82.
Khatereh A, Koruosh G, Alireza T, Daryuosh J, Parastoo B. Adverse events following immunizations in infants under 1 year of age in Lorestan Province, Western Iran. J Prev Med Public Heal [Internet]. 2023 Mar 31;56(2):172–9.
Khazaei Z, Moradi G, Zahraei SM, Gouya MM, Goodarzi E, Yaghini F, et al. The Comparison of the Adverse Events of Pentavalent Vaccine and DPT Vaccine in 2–6 Months Infants in Iran: A National Study. Ann Glob Heal [Internet]. 2020 Feb 3;86(1):11.
Karami M, Ameri P, Bathaei J, Berangi Z, Pashaei T, Zahiri A, et al. Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran. BMC Immunol [Internet]. 2017 Dec 23;18(1):42.
Paramkusham V, Palakurthy P, Gurram N sri, Talla V, Vishwas HN, Jupally VR, et al. Adverse events following pediatric immunization in an Indian city. Clin Exp Vaccine Res [Internet]. 2021;10(3):211.
Ma’rifati L, Udijono A, Kusariana N. Barrier perception factors affecting the acceptance of the COVID-19 vaccine in Salatiga City. J Berk Epidemiol [Internet]. 2023 Jan 29;11(1):60–7.
- Every manuscript submitted to must observe the policy and terms set by the Jurnal Berkala Epidemiologi
- Publication rights to manuscript content published by the Jurnal Berkala Epidemiologi is owned by the journal with the consent and approval of the author(s) concerned. (download copyright agreement)
- Complete texts of electronically published manuscripts can be accessed free of charge if used for educational and research purposes according to copyright regulations.
JBE by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
